Made Scientific Bolsters Board with Manufacturing and Strategy Experts
Event summary
- Made Scientific added Ted Dolan and Soyoung Park to its Board of Directors on April 30, 2026.
- The company's Board now includes six members with expertise in CDMO operations, global commercialization, and strategic planning.
- Made Scientific is expanding its GMP manufacturing capacity in Princeton, NJ, to meet increasing demand from advanced therapy developers.
- The company is supported by long-term strategic shareholder GC Corporation.
The big picture
Made Scientific's Board additions reflect a strategic focus on scaling up cell therapy manufacturing capabilities. The company is positioning itself to support late-phase and commercial programs, aligning with broader industry trends toward increased demand for advanced therapy manufacturing. With GC Corporation's backing, Made Scientific aims to prioritize long-term growth over short-term outcomes, setting the stage for potential shifts in the competitive landscape.
What we're watching
- Governance Dynamics
- How the new Board members will influence Made Scientific's strategic direction and operational execution.
- Scale-Up Challenges
- Whether Made Scientific can successfully expand its GMP manufacturing capacity while maintaining operational discipline.
- Competitive Positioning
- The pace at which Made Scientific can differentiate itself from competitors like Lonza and BioVectra in the cell therapy manufacturing space.
Related topics